Patents by Inventor Melanie Ott

Melanie Ott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190338289
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 7, 2019
    Inventors: Melanie Ott, Daniela Boehm
  • Patent number: 10351853
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 16, 2019
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Daniela Boehm
  • Patent number: 10004751
    Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 26, 2018
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Melanie Ott, Andrew S. Kondratowicz, Nevan John Krogan, Priya Shirish Shah, Krystal Ann Fontaine
  • Publication number: 20180002699
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Application
    Filed: April 14, 2017
    Publication date: January 4, 2018
    Inventors: Melanie Ott, Daniela Boehm
  • Publication number: 20170209460
    Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 27, 2017
    Inventors: Melanie Ott, Andrew S. Kondratowicz, Nevan John Krogan, Priya Shirish Shah, Krystal Ann Fontaine
  • Publication number: 20150133434
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency vims. The methods generally involve contacting an HIV-infected cell in which HIV is latent with an agent that binds a bromodomain (BRD) in the cell. Latently infected cells contain replication-competent integrated HIV-1 genomes that are blocked at the transcriptional level, resulting in the absence of viral protein expression. The present disclosure provides methods for reducing the reservoir of latent immunodeficiency virus in an individual.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 14, 2015
    Inventors: Melanie Ott, Eric M. Verdin, Ming-Ming Zhou
  • Publication number: 20150098926
    Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 9, 2015
    Inventors: Melanie Ott, Eva Herker, Robert V. Farese, Charles Harris
  • Patent number: 8748464
    Abstract: The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4+ T cells.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: June 10, 2014
    Assignee: The J. David Gladstone Institutes
    Inventors: Eric M. Verdin, Melanie Ott, Hye-Sook Kwon, Hyungwook Lim
  • Patent number: 8580492
    Abstract: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: November 12, 2013
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Sara Pagans Lista
  • Publication number: 20120108500
    Abstract: The present disclosure provides methods of modulating immunodeficiency virus transcription, involving modulating enzymatic activity and/or levels of a lysine-specific demethylase-1 (LSD1) polypeptide and/or LSD1-mediated demethylation of methylated Tat. The present disclosure also provides method of identifying agents that modulate LSD1-mediated demethylation of a human immunodeficiency virus (HIV) Tat polypeptide.
    Type: Application
    Filed: October 4, 2011
    Publication date: May 3, 2012
    Inventors: Naoki Sakane, Melanie Ott
  • Publication number: 20120028912
    Abstract: The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.
    Type: Application
    Filed: November 2, 2009
    Publication date: February 2, 2012
    Inventors: Ming-Ming Zhou, Aneel K. Aggarwal, Melanie Ott, Eric Verdin
  • Publication number: 20110318377
    Abstract: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.
    Type: Application
    Filed: September 12, 2011
    Publication date: December 29, 2011
    Inventors: Melanie Ott, Sara Pagans Lista
  • Patent number: 8034350
    Abstract: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: October 11, 2011
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Sara Pagans Lista
  • Publication number: 20110243894
    Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Inventors: Melanie Ott, Eva Herker, Robert V. Farese, Charles Harris
  • Publication number: 20110110891
    Abstract: The present disclosure provides methods of treating a hepatitis C virus infection. The methods generally involve administering to an individual in need thereof an effective amount of an active agent that inhibits a RAS-RAF-MEK-ERK signal transduction pathway.
    Type: Application
    Filed: May 11, 2009
    Publication date: May 12, 2011
    Inventors: Melanie Ott, Eva Herker
  • Publication number: 20100330114
    Abstract: The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4+T cells.
    Type: Application
    Filed: July 16, 2010
    Publication date: December 30, 2010
    Inventors: ERIC M. VERDIN, MELANIE OTT, HYE-SOOK KWON, HYUNGWOOK LIM
  • Publication number: 20100160262
    Abstract: The present invention provides treatment methods involving modulating a sirtuin activity and/or a sirtuin mRNA and/or a sirtuin polypeptide level. In some embodiments, the present invention provides treatment methods involving modulating SIRT1 activity and/or SIRT mRNA and/or polypeptide level. The present invention provides methods of inhibiting SIRT1 Tat deacetylase activity. Methods of inhibiting SIRT1 Tat deacetylase activity are useful for treating immunodeficiency virus infections, particularly human immunodeficiency virus (HIV) infection. Thus, the present invention provides methods of treating an immunodeficiency virus infection, generally involving inhibiting SIRT1 Tat deacetylase activity. The present invention further provides methods of identifying agents that modulate sirtuin activity (e.g., SIRT1 activity), particularly ability of sirtuins to interact with (e.g., bind and/or deacetylate) a substrate, e.g., a viral substrate such as a Tat polypeptide.
    Type: Application
    Filed: December 23, 2008
    Publication date: June 24, 2010
    Inventors: Melanie Ott, Eric M. Verdin, Manfred Jung
  • Publication number: 20090233267
    Abstract: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.
    Type: Application
    Filed: August 12, 2008
    Publication date: September 17, 2009
    Inventors: Melanie Ott, Sara Pagans Lista
  • Patent number: 7589167
    Abstract: The present invention provides the structural determination of a bromodomain determined by NMR spectroscopy. The present invention also provides binding partners for the bromodomain. The present invention further provides the structural determination of the Tat-P/CAF binding complex determined by NMR spectroscopy. In addition, the present invention provides methodology for related drug discovery using high throughput drug screening or structure based rational drug design using the three-dimensional data.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: September 15, 2009
    Assignees: J. David Gladstone Institutes, Mt. Sinai School of Medicine
    Inventors: Ming-Ming Zhou, Aneel K. Aggarwal, Eric Verdin, Melanie Ott
  • Patent number: 7485416
    Abstract: The present invention provides treatment methods involving modulating a sirtuin activity and/or a sirtuin mRNA and/or a sirtuin polypeptide level. In some embodiments, the present invention provides treatment methods involving modulating SIRT1 activity and/or SIRT mRNA and/or polypeptide level. The present invention provides methods of inhibiting SIRT1 Tat deacetylase activity. Methods of inhibiting SIRT1 Tat deacetylase activity are useful for treating immunodeficiency virus infections, particularly human immunodeficiency virus (HIV) infection. Thus, the present invention provides methods of treating an immunodeficiency virus infection, generally involving inhibiting SIRT1 Tat deacetylase activity. The present invention further provides methods of identifying agents that modulate sirtuin activity (e.g., SIRT1 activity), particularly ability of sirtuins to interact with (e.g., bind and/or deacetylate) a substrate, e.g., a viral substrate such as a Tat polypeptide.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: February 3, 2009
    Assignee: The Regents of the University of California
    Inventors: Melanie Ott, Eric M. Verdin, Manfred Jung